New hope for chronic mouth condition: baricitinib trial launches
NCT ID NCT06158113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether baricitinib, a drug used for arthritis, can help people with moderate to severe oral lichen planus—a painful mouth condition. Ten adults who haven't improved with other treatments will take the drug for six months. Researchers will measure changes in mouth sores and quality of life, and watch for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LICHEN PLANUS, MUCOSAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UNC Dermatology and Skin Cancer Center
Chapel Hill, North Carolina, 27516, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid gel quiet oral lichen planus by altering MicroRNAs?
- A pharmacist in the dentist's chair: could a new team approach tame stubborn mouth conditions?
- New oral spray aims to ease sore throat and canker sores without drugs
- Gum disease link in mouth condition under investigation
- Scientists hunt for clues to why lichen planus treatment fails
- 300 patients tracked to uncover hidden cancer risks in common mouth condition